An open-label dose-finding and proof of concept study for Probody Therapeutics (Probody Tx) in subjects with metastatic or locally advanced unrespectable solid tumors and/or lymphomas
Brief description of study
If you have been diagnosed with a metastatic or advanced unresectable solid tumor or lymphoma, you may qualify for this study evaluating the investigational drug CX-072. The main goal of this Phase i study is to evaluate the effectiveness, safety and tolerability of the drug CX-072 when given alone or in combination with ipilimumab or vemurafenib in patients with metastatic or advanced unresectable solid tumors or lymphomas.
Clinical Study Identifier: s16-01257
ClinicalTrials.gov Identifier: NCTs16-01257
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
